Tonix Pharmaceuticals (NASDAQ:TNXP) announced the appointment of Ganesh Kamath as its head of market access, effective September 29, 2025.
The biotechnology company said Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix.
“Ganesh brings deep expertise in market access and a history of delivering results at leading global organizations, including Bayer HealthCare, Hutchmed International, and CuriaGlobal,” Tonix Pharmaceuticals executive vice president commercial Thomas Englese said in a statement.
“As we prepare for the commercial launch of Tonmya and continue advancing our pipeline, his leadership in pricing, contracting, and payer engagement will help ensure patients have timely access to our therapies while driving operational momentum across the business.”
Tonix noted the US launch of Tonmya is expected in the fourth quarter of 2025.
On August 15, 2025, the US Food and Drug Administration (FDA) approved Tonmya for the treatment of fibromyalgia in adults, the first new fibromyalgia therapy in more than 15 years.